Frontiers in Clinical Drug Research - CNS and Neurological Disorders

Mostrar otras versiones (2)
Detalles Bibliográficos
Clasificación:Libro Electrónico
Autor principal: Atta-ur-Rahman
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Sharjah : Bentham Science Publishers, 2016.
Colección:Frontiers in Clinical Drug Research - CNS and Neurological Disorders Ser.
Temas:
Central nervous system.
Central Nervous System
Système nerveux central.
Central nervous system
Acceso en línea:Texto completo
Tabla de Contenidos:
  • Intro
  • CONTENTS
  • PREFACE
  • List of Contributors
  • Multiple Sclerosis Drug Therapy: From the Classical Pharmaceutical Down to Cellular and Molecular Approach
  • MULTIPLE SCLEROSIS
  • Epidemiology, Environmental Agents and Genetics
  • Pathogenesis
  • Animal Models
  • Different Immune System Players on the MS Stage
  • T-cells
  • B-cells
  • Other Immune System Cells and the Innate Immune Response
  • Histopathology
  • Active Lesions
  • Chronic Plaques
  • Remyelinated Plaques
  • Clinical Features and Diagnostic Criteria
  • DISEASE-MODIFYING DRUGS
  • Steroids
  • Injectable Drugs
  • Beta-Interferons
  • Glatiramer Acetate
  • Oral Drugs
  • Teriflunomide
  • Dimethyl Fumarate (DMF, BG-12)
  • Fingolimod (FTY720)
  • Conventional Immunosuppressants
  • Cyclophosphamide
  • Azathioprine
  • Mitoxantrone
  • Laquinimod
  • Methotrexate
  • Biologics (Monoclonal Antibodies)
  • Natalizumab
  • Alemtuzumab (Campath-1H)
  • RECENT EMERGING BIOLOGICAL AND EXPERIMENTAL THERAPEUTICAL APPROACHES
  • B-Cells
  • Rituximab
  • Ocrelizumab and Ofatumumab
  • MEDI-551
  • Mast Cells
  • Masitinib mesylate
  • Cytokines and Chemokines
  • Daclizumab
  • Tabalumab (LY2127399)
  • MOR103
  • Secukinumab
  • I.5.2. PSEN1/PSEN2
  • I.5.3. APOE
  • I.5.4 . APOJ/CLU
  • I.5.5. The Role of Genetic Testing in Clinical Care
  • II. THE ROLE OF BIOMARKERS IN EARLY DIAGNOSIS AND CLINICAL TRIALS ASSESSMENT
  • II.1. Biochemical Markers
  • II.1.1. Cerebrospinal Fluid Biomarkers
  • II.1.2. Blood Biomarkers
  • II.2. Imaging-based Biomarkers
  • II.2.1. Structural Magnetic Resonance Imaging
  • II.2.2. Diffusion Tensor Imaging
  • II.2.3. Functional Magnetic Resonance Imaging
  • II.2.4. Proton Magnetic Resonance Spectroscopy
  • II.2.5. Fluorodeoxyglucose-Positron Emission Tomography
  • II.2.6. Amyloid-Positron Emission Tomography
  • II.3. The Continuum of AD: Diagnosis and Prognosis
  • II.4. Regulatory Framework
  • III. PROSPECTIVE THERAPIES
  • III.1. Non-immunologic Therapies
  • III.1.1. Clinical Trials
  • III.1.2. Preclinical Studies
  • III.2. Immunotherapy
  • III.2.1. Active Immunotherapy
  • III.2.2. Passive Immunotherapy
  • CONCLUSION AND FUTURE PERSPECTIVES
  • CONFLICT OF INTEREST
  • FUNDING
  • ACKNOWLEDGMENTS
  • REFERENCES
  • At the Crossroad between Neuronal Hyperexcitability and Neuroinflammation: New Therapeutic Opportunities for Alzheimer's Disease?
  • INTRODUCTION

Ejemplares similares